Increasing share of voice for an
emerging CRISPR therapeutics startup
![emendo-logo-color emendo-logo-color](https://cglife.com/wp-content/uploads/2023/11/emendo-logo-color.png)
![emendo-logo-color emendo-logo-color](https://cglife.com/wp-content/uploads/2023/11/emendo-logo-color.png)
Challenge
Emendo Biotherapeutics is aiming its precisely engineered CRISPR gene editing platform at providing new hope for currently untreatable genetic disorders. As a late-stage startup poised for rapid growth, they needed fresh media momentum around their technologies and expert executive team to attract potential partners and investors.
Solution
CG Life’s quick-start media relations campaign boosted their media share of voice, elevated the EmendoBio brand and C-suite executives, and showcased their best-in-class technical differentiators. Our carefully crafted technical messaging and big-picture narratives positioned the brand perfectly for upcoming funding rounds and important clinical milestones.
![CG-5508_Emendo-Bio-Collage-Image-01](https://cglife.com/wp-content/uploads/2023/11/CG-5508_Emendo-Bio-Collage-Image-01-scaled.jpg)
![CG-5508_Emendo-Bio-Collage-Image-01](https://cglife.com/wp-content/uploads/2023/11/CG-5508_Emendo-Bio-Collage-Image-01-scaled.jpg)
Broadcast/Podcast/Live Interviews, Media Commentary, Thought Leadership Byline Articles, Targeted Social Media
David Baram – CRISPR Interview – BIO CEO 2023
Results
In just 6 months, CG Life built incredible momentum in the media
and captured the full attention of our target demographics.